Discovery/R&D

41. Leveraging Lymph Nodes With Elicio's Dr. Peter DeMuth 10/30/2022

    MIT-born startup Elicio Therapeutics' novel Amphiphile Technology Platform is designed to directly engage the lymphatic system in the deployment and delivery of therapeutic payloads. We caught up with Chief Scientific Officer Peter DeMuth, Ph.D. at Elicio HQ in Boston to learn how the platform works, and how it's driving rapid clinical progress for the company's robust pipeline of therapeutic vaccines in oncology, as a cell therapy amplifier in liquid and solid tumor indications, and in prophylactic vaccines for infectious diseases like COVID-19. Dr. DeMuth also shares his journey as a young scientific founder, how he's managed the transition from academic scientist to the C-suite, and how he leans into his scientific training to make a killer home brew.

42. Bio Career Moves With Codagenix's Johanna Kaufmann, Ph.D. 10/11/2023

    On this week's episode of the Business of Biotech, Dr. Johanna Kaufmann gives us an intimate retrospective on her career to date, sharing stories about her rapid ascension from Scientist 1 to executive leadership. We dig into her wild ride through M&A, her time at GSK, and the professional and personal development regimens she subscribes to.

43. BoB@JPM: Gene Writing With Tessera's Michael Severino, M.D. 2/26/2023

    Flagship Pioneering plucked Michael Severino, M.D. away from AbbVie to run point at Tessera, a startup it's backed to pioneer a new category of genetic medicine it calls gene writing. The Business of Biotech caught up with Severino at the JP Morgan Healthcare Conference in San Francisco last month. We learned what lured him away from leadership positions at Merck, Amgen, and AbbVie, how gene writing differs from gene therapy and gene editing, why the team at Tessera believes its technologies can write and rewrite DNA at the scales necessary to cure most genetic diseases, and where he plans to take the company from here. 

44. ML-Enabled Drug Discovery With LabGenius' James Field, Ph.D. 7/6/2023

    We explore the intersection of tech and bio with Dr. James Field, founder and CEO of LabGenius. If you're concerned with what ML will do to — or for — your biopharma business, don't miss this episode

45. Med Device Meets Biopharma With OncoSec's Dan O'Connor, J.D. 5/17/2021

    OncoSec CEO & Director Dan O'Connor, J.D. joins the Business of Biotech to discuss his company's development of proprietary application and injection technologies for direct delivery of its pipeline of immunotherapeutic candidates and combination therapies into the tumor environment. O'Connor shares leadership lessons gleaned from his service as a Captain in the United States Marine Corps during Operation Desert Shield, and how he's applied those lessons as his company charts the manufacturing and regulatory challenges along its unique development timeline.

46. Turning The Liver Into A mAb Factory With Homology's Arthur Tzianabos, Ph.D. 11/15/2021

    Homology Medicines' approaches to gene therapy and gene editing have the potential to seriously disrupt both the cell/gene therapy space \_and\_ the mAb manufacturing and administration paradigms as we know them. On this episode of the Business of Biotech, Homology President & CEO Arthur Tzianabos, Ph.D. shares the company's approach and supports its rationale for investing in its own development and manufacturing capacity.

47. Pyxis Oncology's Lara Sullivan, M.D. On Site-Specific ADCs And Change Management 6/20/2022

    To fully appreciate the work Pyxis Oncology is doing in its development of site-specific ADCs for a number of oncological indications under the leadership of Lara Sullivan, M.D., you need to understand the work that shaped her leadership style. On this episode of the Business of Biotech, Dr. Sullivan shares the science and technology driving progress at Pyxis, but she also serves up a master class on change management, honed during her tenure managing high-stakes product portfolios at Pfizer. If you want to be a better leader, don't miss this one.

48. Antibody Cocktails With Immunome's Dr. Purnanand Sarma 7/6/2022

    Immunome CEO Purnanand Sarma, Ph.D. joins the Business of Biotech for a discussion on precision antibodies and his company's discovery platform, which identifies novel therapeutic antibodies and their antigen targets by leveraging highly educated memory B cells from patients who have learned to fight off their disease. It’s kind of like picking an all-star team of players who have been in the game, and who are well-trained to win. On today's episode we'll learn how they’re discovered, how they’re developed, and how they’re applied in cancer and coronavirus.

49. Genomically-Guided Medicine with Elevation Oncology's Shawn Leland, PharmD, RPh 12/13/2021

    Elevation Oncology is taking a new approach to leveraging the genome to guide development of its precision therapeutic development efforts. Its first step is improving both the accuracy of and accessibility to genomic testing for cancer patients. In tandem, the company is in the clinic with its lead candidate seribantumab for cancer patients with a solid tumor of any origin that expresses a genomic change called an NRG1 fusion. On this episode of the Business of Biotech, Founder & CEO Shawn Leland, PharmD, RPh takes us inside the company's unique approach. 

50. mRNA Upstarts With Radar Therapeutics' Sophia Lugo and Eerik Kaseniit, Ph.D. 8/25/2024

    Guest co-host Anna Rose Welch of Advancing RNA fame joins us on this week’s Business of Biotech podcast for a conversation with the leaders of RNA upstart Radar Therapeutics. The company’s co-founders, Eerik Kaseniit, Ph.D. (CSO & President) and Sophia Lugo (CEO), are making waves in the mRNA therapeutics space on the heels of the invention of a precision-expressed mRNA technology that laid bare the path to Radar’s inception.